TY - JOUR
T1 - Corrigendum to “The Role of Stereotactic Ablative Body Radiotherapy in Renal Cell Carcinoma” [Eur Urol 2022] (European Urology, (S030228382202468X), (10.1016/j.eururo.2022.06.017))
AU - Ali, Muhammad
AU - Mooi, Jennifer
AU - Lawrentschuk, Nathan
AU - McKay, Rana R.
AU - Hannan, Raquibul
AU - Lo, Simon S.
AU - Hall, William A.
AU - Siva, Shankar
N1 - Publisher Copyright:
© 2022 European Association of Urology
PY - 2022/11
Y1 - 2022/11
N2 - The authors regret that Section 3.9, paragraph, In a prospective phase II clinical trial, Tang et al. [35] evaluated the feasibility and efficacy of definitive intent radiotherapy in 30 mRCC patients with fewer than six lesions. Feasibility was defined as completion of SABR with <7 d of unplanned break, and efficacy was defined as 1-yr PFS of 70%. Patients received SABR for all lesions and were maintained off systemic therapy. While the efficacy objective was not met, at a median follow-up of 17.5 mo, the trial demonstrated impressive 1-yr PFS and systemic therapy–free survival of 64% and 82%, respectively, with two grade 3 and one grade 4 (hyperglycaemia) adverse events should read as follows: “In a prospective phase II clinical trial, Tang et al. [35] evaluated the feasibility and efficacy of definitive intent radiotherapy in 30 mRCC patients with fewer than six lesions. Feasibility was defined as completion of SABR with <7 d of unplanned break. Patients received SABR for all lesions and were maintained off systemic therapy. At a median follow-up of 17.5 mo, the trial demonstrated impressive 1-yr PFS and systemic therapy–free survival of 64% and 82%, respectively, with two grade 3 and one grade 4 (hyperglycaemia) adverse events” Table 1 row (Correa et al.) column (Dose (Gy)/fraction) should read 26/1, 30–40/3–5. The authors would like to apologise for any inconvenience caused.
AB - The authors regret that Section 3.9, paragraph, In a prospective phase II clinical trial, Tang et al. [35] evaluated the feasibility and efficacy of definitive intent radiotherapy in 30 mRCC patients with fewer than six lesions. Feasibility was defined as completion of SABR with <7 d of unplanned break, and efficacy was defined as 1-yr PFS of 70%. Patients received SABR for all lesions and were maintained off systemic therapy. While the efficacy objective was not met, at a median follow-up of 17.5 mo, the trial demonstrated impressive 1-yr PFS and systemic therapy–free survival of 64% and 82%, respectively, with two grade 3 and one grade 4 (hyperglycaemia) adverse events should read as follows: “In a prospective phase II clinical trial, Tang et al. [35] evaluated the feasibility and efficacy of definitive intent radiotherapy in 30 mRCC patients with fewer than six lesions. Feasibility was defined as completion of SABR with <7 d of unplanned break. Patients received SABR for all lesions and were maintained off systemic therapy. At a median follow-up of 17.5 mo, the trial demonstrated impressive 1-yr PFS and systemic therapy–free survival of 64% and 82%, respectively, with two grade 3 and one grade 4 (hyperglycaemia) adverse events” Table 1 row (Correa et al.) column (Dose (Gy)/fraction) should read 26/1, 30–40/3–5. The authors would like to apologise for any inconvenience caused.
UR - http://www.scopus.com/inward/record.url?scp=85136624037&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85136624037&partnerID=8YFLogxK
U2 - 10.1016/j.eururo.2022.08.018
DO - 10.1016/j.eururo.2022.08.018
M3 - Comment/debate
C2 - 36041935
AN - SCOPUS:85136624037
SN - 0302-2838
VL - 82
SP - e152
JO - European urology
JF - European urology
IS - 5
ER -